AGENUS INC. (NASDAQ:AGEN) Files An 8-K Other Events
Item 8.01 Other Events.
Agenus Inc. (the Company) announced today that the first patient
has been dosed in the Companys Phase 1/2 clinical trial of its
anti-PD-1 antibody, AGEN2034. The open-label, dose-escalation
portion of the trial is designed to evaluate the safety and
pharmacological activity of AGEN2034 in patients with advanced
solid tumors. Part 2 of the trial is planned to evaluate the
recommended dose of AGEN2034 in patients with second line
cervical cancer. Preliminary safety and efficacy data are
expected to be available within the next 9-12 months.
AGEN2034 is an antagonist antibody targeting programmed death 1,
or PD-1. PD-1 is an inhibitory receptor expressed on activated T
cells. When this receptor interacts with PD-L1 and/or PD-L2
molecules expressed on cancer cells, the T cells ability to kill
cancer cells is neutralized. Therefore, blocking PD-1 with
AGEN2034 may allow T cells to recognize and kill tumor cells.
The full text of the press release issued in connection with the
announcement is attached hereto as Exhibit 99.1 and is
incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description of Exhibit |
| 99.1 | Press Release dated April 20, 2017. |
About AGENUS INC. (NASDAQ:AGEN)
Agenus Inc. (Agenus) is an immuno-oncology company. The Company is engaged in discovering and developing treatments for patients with cancer. Its approaches are driven by platforms and programs, which include antibody discovery platform, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage and AutoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company has a portfolio of programs in various stages of development, including a series of antibodies in discovery and pre-clinical and clinical development, Prophage vaccine, a Heat Shock Protein (HSP)-based vaccine candidate for a form of brain cancer that has completed Phase II trials, and a number of QS-21 Stimulon-containing vaccine candidates in late stage development. AGENUS INC. (NASDAQ:AGEN) Recent Trading Information
AGENUS INC. (NASDAQ:AGEN) closed its last trading session 00.00 at 3.39 with 794,763 shares trading hands.
